GlassScriptPhysician profile
Danielle Palaferro
NPI 1366066086
$2,016.01
in general payments reported to CMS, 2019-2025
19 companies · $987 in 2025
The $987 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $138 · 2024: $891 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Education: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.10 |
| Education | $476.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $392.92 | 2024-2025 | |
| Glaxosmithkline, LLC. | $340.92 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Jazz Pharmaceuticals INC. | $271.49 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $143.82 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Sobi, INC | $142.69 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $140.53 | 2023-2024 | Opdivo |
| Gilead Sciences, INC. | $121.83 | 2024 | Trodelvy |
| Incyte Corporation | $109.12 | 2025 | Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $66.61 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $54.93 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $54.73 | 2024 | Ocrevus Zunovo, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $27.61 | 2024 | Ninlaro |
| Servier Pharmaceuticals LLC | $24.71 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.53 | 2025 | |
| Janssen Biotech, INC. | $21.98 | 2025 | Carvykti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $21.80 | 2024 | Kimmtrak |
| Exelixis INC. | $21.60 | 2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $17.64 | 2025 | Romvimza, Qinlock |
| Amgen INC. | $17.55 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Palaferro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.